We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study.
- Authors
Du, Liying; Huo, Liman; Hou, Juan; Zhou, Xiajin; Liu, Mingfeng; Guo, Teng; Wang, Wei; Chen, Huihui; Chen, Xinran
- Abstract
Blood concentration monitoring plays an important role in the rational use of norvancomycin. However, the reference interval for the norvancomycin plasma concentration in the treatment of infections in hemodialysis patients with end stage kidney disease is undefined. To determine the safe and effective interval for the norvancomycin plasma trough concentration, 39 patients treated with hemodialysis and norvancomycin were analyzed retrospectively. The norvancomycin plasma concentration before hemodialysis was tested as the trough concentration. The associations of the norvancomycin trough concentration with efficacy and adverse reactions were evaluated. No norvancomycin concentration above 20 μg/mL was detected. The trough concentration, but not the dose, had a significant effect on the anti‐infectious efficacy. Compared with the low norvancomycin trough concentration group (<9.30 μg/mL), the high concentration group (9.30–20.0 μg/mL) had improved efficacy (OR = 15.45, p < 0.01) with similar side effects (OR = 0.5417, p = 0.4069). It is beneficial to maintain the norvancomycin trough concentration at 9.30–20.0 μg/mL to achieve a good anti‐infectious effect in hemodialysis patients with end stage kidney disease. Plasma concentration monitoring provides a data basis for the individual treatment of infections with norvancomycin in hemodialysis patients.
- Subjects
HEMODIALYSIS patients; KIDNEY diseases; PATIENT monitoring; COHORT analysis; RETROSPECTIVE studies
- Publication
Biopharmaceutics & Drug Disposition, 2023, Vol 44, Issue 2, p175
- ISSN
0142-2782
- Publication type
Article
- DOI
10.1002/bdd.2354